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Pre-exposure prophylaxis (PrEP), the use of antiretrovirals (ARVs) by human immunodeficiency virus (HIV)–
uninfected individuals to prevent acquisition of the virus during high-risk sexual encounters, enjoyed its first 2
major successes with the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 and the
Pre-Exposure Prophylaxis Initiative (iPrEx). These successes were buoyed by additional positive results from
the TDF2 and Partners PrEP trials. Although no seroconverters in either arm of CAPRISA developed resistance
to tenofovir, 2 participants in iPrEx with undetected, seronegative acute HIV infection were randomized to
receive daily oral tenofovir-emtricitabine and resistance to emtricitabine was later discovered in both men.
A similar case in the TDF2 study resulted in resistance to both ARVs. These cases prompted us to examine
existing literature on the nature of resistance mutations elicited by ARVs used for PrEP. Here, we discuss the
impact of signature mutations selected by PrEP, how rapidly these emerge with daily ARV exposure, and the
individual-level and public health consequences of ARV resistance.
As we enter the fourth decade of the human immuno-
deficiency virus (HIV) infection pandemic, [1] 4 ran-
domized, controlled trials have delivered the first
tangible successes in the science of pre-exposure pro-
phylaxis (PrEP). In 2010, the Centre for the AIDS Pro-
gramme of Research in South Africa (CAPRISA) 004
demonstrated a 39% reduction in HIV transmission
among heterosexual South African women who used
a tenofovir-based vaginal gel before and after sex [2].
Several months later came findings from the Pre-
Exposure Prophylaxis Initiative (iPrEx), a study of daily
oral tenofovir-emtricitabine among transgendered
women and men who have sex with men, which showed
a 44% decrease in incident HIV infections compared
with placebo [3]. In both studies, increased adherence to
study medication was associated with even greater pro-
tection [2, 3].
At the 2011 International AIDS Society Conference in
Rome, Italy, positive results were reported from 2 addi-
tional studies of PrEP among heterosexual individuals.
The TDF2 study showed 63% protective efficacy of daily
tenofovir-emtricitabine among sexually active men and
women [4], whereas the Partners PrEP trial of sero-
discordant couples demonstrated 62% and 73% reduc-
tions in transmission for daily oral tenofovir and
tenofovir-emtricitabine, respectively [5].
Lost in the excitement over these promising results is
any significant discussion about the potential for anti-
retroviral (ARV) resistance todevelop amongpersonswho
are administeredPrEP.Among the38women inCAPRISA
randomized to receive tenofovir gel who became HIV-
infected, no tenofovir-associated resistance mutations
were detected using population (bulk) sequencing [2].
Deep sequencing of samples from the seroconverters of
CAPRISA to detect low-frequency resistant variants is
currently underway (S. A. Karim, written communica-
tion, April 2011). Analyses of resistance are also ongoing
for Partners PrEP [5].
Resistance in iPrEx and the TDF2 trial is a dif-
ferent story. In iPrEx, seroconversion occurred in 38
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participants on the tenofovir-emtricitabine arm, including 2 men
who had seronegative acute HIV infection at the time of ran-
domization; both of these men went on to receive active drug. By
week 4, both had evidence of resistance to emtricitabine, although
only 1 of the 2 was confirmed to have developed the mutation as
a result of study drug exposure [6]. For the other participant, it
remains unclear whether the resistance mutation was transmitted
(primary) or acquired. In the TDF2 study, 1 participant with
unrecognized acute HIV infection initiated tenofovir-em-
tricitabine and developed resistance to both ARV agents [4].
These cases of resistance, emerging when PrEP functionally
became incompletely suppressive ARV therapy, provide a useful
starting point for inquiries into the consequences of PrEP in
terms of drug resistance and its implications for public health.
Here, we address several critical questions facing clinicians,
public health practitioners, and policy-makers by examining
existing literature on resistance to the ARVs utilized for PrEP.




Signature mutations for emtricitabine occur at codon 184. Single-
nucleotide alterations mediate amino acid changes from methi-
onine to isoleucine (M184I) or valine (M184V) [7, 8], resulting in
extremely high-level resistance to both emtricitabine and its
congener, lamivudine. Although it is perhaps counterintuitive,
trials from the early 1990s onward have demonstrated benefits in
viral load suppression when lamivudine is kept in regimens fol-
lowing the emergence of the M184V mutation [9, 10]; given the
similarities between lamivudine and emtricitabine, the same effect
is assumed to occur with emtricitabine. Three principal hypoth-
eses have been proposed to explain why lamivudine and em-
tricitabine remain useful despite the presence of M184V. First,
continued drug exposure maintains the selection pressure eliciting
M184V, and viruses carrying this particular mutation demon-
strate markedly decreased replicative capacity [11, 12]. Second,
a combination of in vitro and in vivo data suggests continued
direct antiretroviral activity despite this mutation [13, 14]. Finally,
increased susceptibility to other nucleoside reverse transcriptase
inhibitors (NRTIs)—especially zidovudine and tenofovir—is in-
duced by the presence of M184V [15].
Tenofovir Disoproxil Fumarate
Mutations at 2 specific codons of reverse transcriptase impact the
efficacy of tenofovir: K65R and K70E/G. The K65R mutation
involves a transition at the second nucleotide position of codon
65, which changes lysine to arginine [16]. This alteration causes an
intermediate level of resistance to tenofovir, abacavir, didanosine,
lamivudine, and emtricitabine [17]. Paradoxically, K65R increases
susceptibility to zidovudine [18]. Molecular biological and clinical
cohort evidence strongly suggests K65R is more likely to develop
among subtype C strains exposed to certain incompletely sup-
pressive ARV regimens [16, 19, 20], including those that contain
tenofovir, stavudine, and didanosine. This observation may be
important for the future of PrEP in the developing world, given
that subtype C accounted for nearly one-half of all infections
globally between 2004 and 2007—especially in India and sub-
Saharan Africa [21].
Similar to K65R, single-nucleotide alterations in codon 70
result in an amino acid shift from lysine (K) to glutamate (E),
with a second purine-to-purine transition required to yield
glycine (K70G) [22]. By itself, K70E/G moderately reduces sus-
ceptibility to tenofovir, didanosine, and abacavir and has slight
negative effects on lamivudine and emtricitabine activity.
HOW RAPIDLY DO EMTRICITABINE- AND
TENOFOVIR-ASSOCIATED RESISTANCE
MUTATIONS DEVELOP?
Although the primary mutations selected by emtricitabine and
tenofovir are mediated by single-nucleotide changes, we know
from a variety of monotherapy and dual-therapy data that em-
tricitabine and lamivudine select for M184V much more rapidly
than tenofovir does for either K65R or K70E/G. Data from animal
models provide further insight into the consequences of in-
completely suppressive single- or dual-agent regimens given for
extended periods.
Monotherapy Studies
Within 15 days, single-agent emtricitabine exposure causes M184V
to develop in 1 in 5 recipients [23]. Earlier work on lamivudine
demonstrated similar results, with a dramatic increase in the
proportion of patients who received lamivudine monotherapy
harboringM184V, from 20% at 2 weeks to 80% at 4 weeks. Within
12 weeks, all 20 participants in the study had the mutation [24].
In sharp contrast to this rapid selection of M184V, 2 separate
studies of tenofovir monotherapy in humans demonstrate that
the drug can be administered for up to 28 days without evidence
of resistance by bulk sequencing [25, 26]. However, among
a group of 12 macaques with established simian/human immu-
nodeficiency virus (SHIV) infection treated with daily single-
agent tenofovir, K70E became detectable by real-time polymerase
chain reaction after a median of 2 weeks. K65R arose at low levels
between 2 and 12 weeks, and a median of 8 weeks of tenofovir
exposure was required before K65R became detectable on bulk
sequencing (range, 4–20 weeks) [27]. This suggests that human
studies of 28-day tenofovir monotherapy ended prior to the point
at which resistance emerges.
Dual-therapy Studies
The most important data on the evolution of resistance under
dual therapy come from NUCA 3001, a randomized trial from
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the mid-1990s comparing monotherapy with zidovudine or
lamivudine to dual therapy with both agents [28]. M184V de-
veloped within 12 weeks in the majority of participants initiating
any lamivudine-containing regimen. After 1 year of treatment,
M184V was detected in 87% of patients receiving dual therapy,
compared with 100% of those receiving lamivudine mono-
therapy. Importantly, only 32% of dual-NRTI recipients de-
veloped mutations conferring zidovudine resistance over the
same period—a significant lag compared with the zidovudine
monotherapy arm, in which 61% of participants had resistance
at 1 year [29].
This trend toward postponed emergence of zidovudine-
associated mutations in the presence of M184V was seen in
a similar study, NUCB 3001, which compared zidovudine plus
lamivudine to zidovudine alone. Among dual-therapy recipients,
95% developed M184V by week 8. When resistance analyses
were performed at the completion of 24 weeks of follow-up, just
25% of patients receiving dual therapy had developed mutations
at zidovudine resistance codons, in contrast to 69% of those
receiving zidovudine monotherapy (P 5 .006) [11].
If M184V similarly delays emergence of tenofovir-associated
mutations, it could have important ramifications for managing
individuals infected despite PrEP. Preserving susceptibility to
tenofovir would allow its future use in combination ARV ther-
apy. Although in vivo data are lacking, the crippled replicative
capacity of K65R1M184V double mutants in vitro supports the
hypothesis that M184V may be ‘‘protective’’ against the acqui-
sition of K65R, at least in non–subtype C isolates [30, 31].
Additional Animal Data
In a study of PrEP among macaques rectally challenged with
SHIV, 6 of 12 animals receiving ARVs developed breakthrough
infection and continued receiving the medications to which they
were originally assigned. Four infections occurred among mac-
aques that received emtricitabine monotherapy, whereas 2 ani-
mals that received tenofovir-emtricitabine became infected [32].
In all instances, the virus that established infection was wild-type.
Two of the 6 animals developed mutations in their viruses:
1 animal with M184I in the tenofovir-emtricitabine arm 3 weeks
after infection and 1 animal with M184V in the emtricitabine-
only arm 10 weeks after infection. Importantly, however, the
macaques that developed M184I/V mutations were the 2 with
the highest peak viremias, suggesting that selection of resistant
mutants may be potentiated by high viral replication [32]—a
hallmark of acute HIV infection [33–35]. In light of this, it is
noteworthy that the presence of ARVs during early infectionmay
blunt peak viremia in human hosts. A case report of failed non-
occupational post-exposure prophylaxis describes seroconver-
sion without any acute retroviral symptoms and a peak viremia
of just 647 copies/mL, 11 days after stopping the planned 28-day
regimen of tenofovir-emtricitabine. The virus establishing
infection was genotypically and phenotypically pan-susceptible
to available ARVs [36].
We can use these data to construct a rough timeline of events
from the date of infection in an individual receiving tenofovir-
emtricitabine–based PrEP to the emergence of resistance under
continued ARV exposure. With daily use, one can expect
M184V to appear between 2 and 4 weeks, with a majority of
recipients harboring the mutation by the 8-week mark. K65R
will likely follow. If there is in reality no significant protective
effect from M184V against the accumulation of other NRTI
mutations, then one could see K65R evolving as early as the
fourth week of treatment. For individuals intermittently ad-
herent to PrEP, the timeline for emergence of mutations may be
very different.
WHAT DO PRE-EXPOSURE PROPHYLAXIS
FAILURES TELL US ABOUT THE EVOLUTION OF
ANTIRETROVIRAL RESISTANCE?
Nonadherence seems to be the main reason for the PrEP failures
observed in CAPRISA and iPrEx. Quite simply, one must actu-
ally use the ARVs for them to prevent infection. Although it is
reasonable to assume that the same is true for TDF2 and Partners
PrEP, the reasons for the lack of any efficacy of daily tenofovir-
emtricitabine among heterosexual women in the FEM-PrEP
study, which was halted in early 2011, remain unclear [37].
Thirty-four of the 36 participants who seroconverted during
the course of iPrEx had samples available for analytical phar-
macology, but only 3 had detectable study drug in their plasma
or peripheral mononuclear cell samples at the time of HIV in-
fection diagnosis [6]. In CAPRISA, tenofovir was detected in
genital tract secretions of just 36% of seroconverters, compared
with 83% of HIV-uninfected women [38]. Of course, these
measurements only function as surrogates for adherence be-
havior, because determinations of ARV levels are not made at
the time of transmission.
The development of resistance could also be viewed as a sur-
rogate for adherence. Consider HIV-infected patients receiving
combination ARV therapy. With very poor adherence, they are
essentially protected from acquiring resistance mutations; in-
sufficient systemic concentrations of drug are present to exert
any meaningful selection pressure on the virus. Among highly
adherent patients, suppression of viral replication eliminates
opportunities for mutations to develop and propagate. Those
patients in the middle of the adherence spectrum are at greatest
risk for resistance.
PrEP presents a more complicated problem. For both topi-
cally and orally administered PrEP, poorly adherent recipients
are unlikely to develop resistance but are more likely to become
HIV-infected; as adherence improves, the risk of HIV acquisi-
tion is reduced. However, with increasing exposure to partially
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suppressive ARVs comes an increasing risk of selecting resistance
mutations. Thus, the absence of detectable resistance among
PrEP recipients who became HIV-infected during iPrEx and
CAPRISA can yield some insight into the minimum level of
adherence needed to select for resistance. Because of the poor
systemic absorption of tenofovir after intravaginal application
[39], women in CAPRISA may have been functionally protected
from developing resistance. Two of the 3 iPrEx participants with
detectable drug levels reported at least 50% adherence, pro-
viding additional circumstantial evidence that the level of ad-
herence required to select for NRTI mutations (detectable by
bulk sequencing) is closer to that of protease inhibitors (85%)
than to that of nonnucleoside reverse transcriptase inhibitors
(NNRTIs; 10%) [40].
WHAT ARE THE CONSEQUENCES OF PRE-
EXPOSURE PROPHYLAXIS FAILURE, IN TERMS
OF ANTIRETROVIRAL RESISTANCE?
The consequences of PrEP failure can be viewed at both individual
and population levels. Consider a hypothetical PrEP recipient with
modest adherence who becomes HIV-infected during a high-risk
sexual encounter. Understandably concerned about the event, this
person begins taking the ARVs as originally prescribed. For this
individual and other, similar individuals, all initial preferred reg-
imen options are potentially compromised. Currently, the World
Health Organization recommends pairing zidovudine or tenofo-
vir with lamivudine or emtricitabine as the dual-NRTI backbone
of efavirenz- or nevirapine-based first-line ARV regimens [41].
M184V markedly reduces susceptibility to both lamivudine and
emtricitabine, enhances the activity of zidovudine and tenofovir,
and leaves efavirenz or nevirapine as the only other fully active
agent in the regimen. Unfortunately, these 2 NNRTIs have low
genetic barriers to resistance; single mutations can cause cross-
resistance, rendering both agents inactive [17]. Second-line regi-
mens involve swapping out the NNRTI for a boosted protease
inhibitor and interchanging zidovudine and tenofovir, depending
on which agent was used in the initial regimen [41]. Thus, M184V
by itself can significantly increase the risk of failure for NNRTI-
based first-line regimens that are the standard of care globally, and
it can impact the efficacy of second-line regimens in resource-
limited settings as well.
On a population level, the principal concerns include the
potential for PrEP to influence the prevalence of resistance and
limited access in the developing world to ARVs beyond second-
line regimens. Transmitted drug resistance, the primary acqui-
sition of a strain of HIV that is already resistant to at least 1 ARV,
ranges in prevalence from 10% to 15% in the United States [42]
and Europe [43], although signature mutations for tenofovir and
emtricitabine consistently occur at very low frequencies among
treatment-naive individuals. M184V is detected in 1%–1.5% of
pretreatment samples; K65R is seen in ,0.5% [42, 43]. Mathe-
matical modeling studies have examined different PrEP efficacies
and the downstream effects on the prevalence of resistance, with
mixed results [44]. Generally, modeling shows that use among
undiagnosed, HIV-infected persons (as in our hypothetical ex-
ample) raises the prevalence of acquired drug resistance, whereas
risk compensation among PrEP users could act to negate its
overall effect on reducing HIV infection incidence [45]. Partners
of individuals who develop resistant HIV infection from expo-
sure to PrEP agents may themselves be partially protected from
infection, owing to reduced transmission efficiency of viruses
with resistance mutations—especially M184V [46].
HOW SHOULD THESE RESISTANCE DATA
GUIDEOURMANAGEMENTOFPRE-EXPOSURE
PROPHYLAXIS AS WE MOVE FORWARD?
What iPrEx, CAPRISA, Partners PrEP, and TDF2 have dem-
onstrated is not the effectiveness of PrEP but rather its efficacy
within structured clinical trials settings. Oral contraceptives offer
a useful analogy: with perfect daily use, 3 out of 1,000 women
will become pregnant, whereas under typical usage conditions,
90 out of 1000 actually become pregnant [47]. It is reasonable to
believe that PrEP will exhibit a similar disparity between efficacy
and effectiveness when brought into mainstream use. In prac-
tice, PrEP recipients will not have the benefit of study monitors
and frequent reminders to get HIV testing. It is precisely that
scenario—partially suppressive ARVs administered over long
periods without close supervision—that heightens the risk of
resistance. If oral tenofovir-emtricitabine is ineffective in certain
subpopulations for reasons other than adherence (as suggested
by the investigators of FEM-PrEP) [37], the risk of resistance will
be present even in the absence of any benefit from daily ARV
prophylaxis.
We also must be cognizant of the role that frequent HIV
testing will play in the long-term success of PrEP and in con-
tainment of resistance should breakthrough infections occur.
Our timeline for resistance mutation emergence suggests that
testing should be at least every month and preferably should use
a sensitive assay capable of detecting early HIV infection (eg,
a fourth-generation antibody/antigen assay or nucleic acid am-
plification testing). However, given 2009 statistics showing that
only 19% of Americans aged 18–64 years received an HIV test in
the past 12 months [48], testing on so frequent a schedule does
not seem plausible. Identifying strategies to pair frequent testing
with PrEP administration should be a research priority, as we
move forward.
Infectious diseases consultants are confronted each day with
the consequences of poor antimicrobial stewardship, and until
now, this responsibility has remained exclusively with medical
providers. However, PrEP changes the equation. For the first
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time, prescribers will be asking patients to become responsible
stewards and counting on them to manage these medications
appropriately. In light of the individual and public health
consequences of PrEP failure, this is a heavy burden to impose
on persons with varying degrees of biomedical understanding.
It is therefore incumbent upon providers to scrutinize candi-
dates for PrEP and make decisions about the appropriateness
of these medications on a case-by-case basis. Prescription of
PrEP indiscriminately will place in jeopardy the long-term
utility of tenofovir and emtricitabine as first-line agents.
Providers must act cautiously and wisely as PrEP becomes
a reality.
SUMMARY
Recent successes with the use of ARVs for HIV infection pro-
phylaxis have understandably sparked excitement among pro-
viders and prevention scientists. This must be tempered with
clear-eyed assessments about potential long-term consequences
of resistance despite benefits of PrEP in the short term. Muta-
tions that impact the efficacy of first-line ARVs can develop in as
little as 2 weeks of daily PrEP administered to HIV-infected
persons, whether the infection was undetected at baseline or
acquired while receiving PrEP. If the prevention of new in-
fections is offset by an increase in resistance and a loss of
principal treatment options, then perhaps the costs of PrEP
outweigh its advantages.
PrEP holds promise as a tool for prevention, but it may not be
the best option for every person at risk for acquiring HIV. As
evaluations of PrEP continue, a principal goal must be to de-
termine a profile of patients who are most likely to benefit from
the intervention—and most likely to comply with a regimented
care plan incorporating both administration of PrEP and fre-
quent HIV testing. Furthermore, studies are needed to de-
termine how best to optimize adherence among PrEP recipients
and how to intervene if the drugs are not taken properly.
None of the challenges posed by PrEP are insurmountable,
but as we move forward with this newest part of our arma-
mentarium, we must act carefully and responsibly—and require
that recipients of PrEP do the same.
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34. Lindbäck S, Karlsson AC, Mittler J, et al. Viral dynamics in primary
HIV-1 infection. AIDS 2000; 14:2283–91.
35. Pilcher CD, Shugars DC, Fiscus SA, et al. HIV in body fluids during
primary HIV infection: implications for pathogenesis, treatment and
public health. AIDS 2001; 15:837–45.
36. Prada N, Davis B, Jean-Pierre P, et al. Drug-susceptible HIV-1 infection
despite intermittent fixed-dose combination tenofovir/emtricitabine as
prophylaxis is associated with low-level viremia, delayed seroconver-
sion, and an attenuated clinical course. J Acquir Immune Defic Syndr
2008; 49:117–22.
37. Miller L. FEM-PrEP June 2011 Update. Available at: http://www.fhi.org/
en/Research/Projects/FEM-PrEP.htm. Accessed 11 July 2011.
38. Kashuba AD, Abdool Karim SS, Kraft E, et al. Do systemic and genital
tract tenofovir concentrations predict HIV seroconversion in the
CAPRISA 004 tenofovir gel trial? [abstract TUSS0502]. In: 18th In-
ternational AIDS Conference. Vienna, Austria, 2010.
39. Mayer KH, Maslankowski LA, Gai F, et al. Safety and tolerability of
tenofovir vaginal gel in abstinent and sexually active HIV-infected and
uninfected women. AIDS 2006; 20:543–51.
40. Bangsberg DR. Preventing HIV antiretroviral resistance through better
monitoring of treatment adherence. J Infect Dis 2008; 197(suppl 3):
S272–8.
41. HIV/AIDS Programme. Antiretroviral therapy for HIV infection in
adults and adolescents: recommendations for a public health approach
(2010 revision). Geneva, Switzerland: World Health Organization,
2010.
42. Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug
resistance associated mutations and HIV-1 subtypes in new HIV-1
diagnoses, U.S.–2006. AIDS 2010; 24:1203–12.
43. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-
resistant HIV-1 variants in untreated individuals in Europe: im-
plications for clinical management. J Infect Dis 2005; 192:958–66.
44. Baggaley RF, Powers KA, Boily MC. What do mathematical models tell
us about the emergence and spread of drug-resistant HIV? Curr Opin
HIV AIDS 2011; 6:131–40.
45. Abbas UL, Hood G, Wetzel AW, Mellors JW. Factors influencing the
emergence and spread of HIV drug resistance arising from rollout of
antiretroviral pre-exposure prophylaxis (PrEP). PLoS One 2011; 6:e18165.
46. Cong ME, Youngpairoj AS, Aung W, et al. Generation and mucosal
transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3
mutants in macaques. Virology 2011; 412:435–40.
47. Trussell J. Contraceptive failure in the United States. Contraception
2011; 83:397–404.
48. Kaiser Family Foundation. 2009 Survey of Americans on HIV/AIDS:
summary of findings on the domestic epidemic, Menlo Park, California:
The Henry J. Kaiser Family Foundation, 2009. Report no. 7889.
1270 d CID 2011:53 (15 December) d HIV/AIDS
